Abbott Labs Still in Slow-Growth Mode
Although the company has some promising products under development, sales and earnings growth are still well below average.
Although the company has some promising products under development, sales and earnings growth are still well below average.
Abbott Laboratories (ABT) has been trying to shake off its lethargy, but its new initiatives probably won't reinvigorate sales until later this year.
In its earnings release this morning, the company said revenues for the first quarter were up about 1% over the previous year. Although the company's hospital-products and Ross Nutritionals lines continued to show decent sales gains, sales were down for the pharmaceutical and diagnostic segments. Earnings were in line with expectations at $0.44 per share.
Abbott's quarterly results suffered partly because of increased generic competition for Hytrin, a medication used to treat high blood pressure and prostate enlargement. Sales on Biaxin, a leading antibiotic, were down about 17% for the quarter because this year's flu season was short and relatively mild. The company also took some significant hits as currency movements cut into international sales.
There are a couple of bright spots on the horizon, though. Abbott has ramped up research and development spending, and it looks like some of its efforts are close to paying off. An FDA advisory committee voted yesterday to recommend approval for Uprima, the company's treatment for erectile dysfunction. In the conference call this morning, management noted that an estimated 30 million men in the United States suffer from the condition and only half of them are currently being treated with other products such as Pfizer's (PFE) Viagra.
Management also has high hopes for its new HIV protease inhibitor, which is currently in phase III clinical trials. The company expects to file for FDA approval for this product, ABT-378, around the middle of this year.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals
and individual investors. These products and services are usually sold through
license agreements or subscriptions. Our investment management business generates
asset-based fees, which are calculated as a percentage of assets under management.
We also sell both admissions and sponsorship packages for our investment conferences
and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.